Cargando…

The impact of thyroid imaging reporting and data system on the management of Bethesda III thyroid nodules()

OBJECTIVES: Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) is a heterogeneous category of fine needle aspiration cytology (FNAC); the management of this condition remains controversial. The clinical significance of such patients relies on the exclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alqahtani, Saad M., Al-Sobhi, Saif S., Alturiqy, Mohammed A., Alsalloum, Riyadh I., Al-Hindi, Hindi N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taibah University 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906009/ https://www.ncbi.nlm.nih.gov/pubmed/36818179 http://dx.doi.org/10.1016/j.jtumed.2022.10.009

Ejemplares similares

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

Weighty Matters: The Obesity–Thyroid Nodule Connection Unveiling the Impact of Obesity on Thyroid Cancer Risk
por: Alqahtani, Saad M., et al.
Publicado: (2023)

Evaluation of thyroid nodules classified as Bethesda category III on FNAC
por: Garg, Shiwani, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Radiofrequency ablation for thyroid Bethesda III nodules: preliminary results
por: Chiang, Pi-Ling, et al.
Publicado: (2023)

Thyroid imaging reporting and data system combined with Bethesda classification in qualitative thyroid nodule diagnosis
por: Tan, Huiwen, et al.
Publicado: (2019)

Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital
por: Al Dawish, Mohamed, et al.
Publicado: (2020)

Managing Bethesda IV thyroid nodules in an iodine-deficient population
por: Badash, Ido, et al.
Publicado: (2023)

Thyroid Nodules Cytopathology Applying the Bethesda System with Histopathological Correlation
por: Zarif, Hawazen A., et al.
Publicado: (2018)

Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
por: Yoo, Mi Ri, et al.
Publicado: (2015)

The Role of “Critical” Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules
por: Orlando, Giuseppina, et al.
Publicado: (2023)

AI diagnosis of Bethesda category IV thyroid nodules
por: Yao, Jincao, et al.
Publicado: (2023)

Hashimoto’s Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System
por: Słowińska-Klencka, Dorota, et al.
Publicado: (2022)

An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules
por: Taccogna, Silvia, et al.
Publicado: (2022)

Malignancy in Thyroid Nodules with Bethesda III Category on Repeat Fine Needle Aspiration Biopsy*
por: Lourdes Ng, Jennifer, et al.
Publicado: (2023)

Treatment Choices in Managing Bethesda III and IV Thyroid Nodules: A Canadian Multi-institutional Study
por: Kuta, Victoria, et al.
Publicado: (2021)

Thyroid Cancer Detection Rate and Associated Risk Factors in Patients with Thyroid Nodules Classified As Bethesda Category III
por: Mileva, Magdalena, et al.
Publicado: (2018)

Malignancy Rate of Bethesda Class III Thyroid Nodules Based on the Presence of Chronic Lymphocytic Thyroiditis in Surgical Patients
por: Cho, Yoon Young, et al.
Publicado: (2021)

Association of thiol/disulphide homeostasis with Bethesda classification of thyroid nodules and thyroid cancer
por: BİLGİNER, Muhammet Cüneyt, et al.
Publicado: (2022)

Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule
por: Li, Fu, et al.
Publicado: (2019)

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience
por: Almahari, Sayed Ali, et al.
Publicado: (2019)

Strain Elastography as a Valuable Diagnosis Tool in Intermediate Cytology (Bethesda III) Thyroid Nodules
por: Stoian, Dana, et al.
Publicado: (2019)

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective
por: Zahid, Adnan, et al.
Publicado: (2021)

Surgical Outcome and Malignant Risk Factors in Patients With Thyroid Nodule Classified as Bethesda Category III
por: Huang, Jianhao, et al.
Publicado: (2021)

Diagnostic value of thyroid imaging reporting and data system combined with BRAF(V600E) mutation analysis in Bethesda categories III–V thyroid nodules
por: Wu, Liuxi, et al.
Publicado: (2022)

Cytological diagnosis of pediatric thyroid nodule in perspective of the Bethesda System for Reporting Thyroid Cytopathology
por: Pantola, Chayanika, et al.
Publicado: (2016)

Correlation between Thyroid Imaging Reporting and Data System and Bethesda System of Reporting of Thyroid Cytopathology of Thyroid Nodule: A Single Center Experience
por: Biswas, Ananya, et al.
Publicado: (2020)

Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study
por: Kars, T U, et al.
Publicado: (2021)

Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center
por: Godoi Cavalheiro, Beatriz, et al.
Publicado: (2017)

Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3
por: Kim, Na Eun, et al.
Publicado: (2023)

Association of ultrasonographically determined anatomical location of Bethesda 3 thyroid nodules with differentiated thyroid cancer
por: Gezer, Emre, et al.
Publicado: (2022)

Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management
por: Chiosea, Simion, et al.
Publicado: (2023)

Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
por: Yoo, Won Sang, et al.
Publicado: (2020)

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
por: Hu, Mimi I, et al.
Publicado: (2021)

Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III–V thyroid nodules
por: Talmor, Guy, et al.
Publicado: (2022)

Malignancy risk in Bethesda class IV thyroid nodules in an iodine deficient region
por: Loderer, Tommaso, et al.
Publicado: (2023)

Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: A PRISMA-compliant systematic review and meta-analysis
por: Gao, Lu-Ying, et al.
Publicado: (2017)

Performance of Afirma genomic sequencing classifier and histopathological outcome are associated with patterns of atypia in Bethesda category III thyroid nodules
por: Jin, Xiaobing, et al.
Publicado: (2022)

Concordance between the TIRADS ultrasound criteria and the BETHESDA cytology criteria on the nontoxic thyroid nodule
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2017)

Ultrasound-Guided Thermal Ablation of Bethesda IV Thyroid Nodules: A Pilot Study
por: Li, Xinyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mjl54v8c4iutl20bvgme0dvt6u